Reliable prognostication using Ki-67 as a solitary biomarker has been validated in a number of cancers, including breast, prostate, cervical, lung, soft tissue, neuroendocrine cancers, and gastrointestinal stromal tumours [40,41,42,43,44,45]. This evidence concerns the gene MKI67 and cancer.